Showing results (241-250 of 262) with videos related to

Sort By:
Pageof 27
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17)Sergio Amadori, Stefan Suciu, Roberto Stasi, et al.
Nature Communications|May 26, 2021
Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patientsFlorent Malard, Anne Vekhoff, Simona Lapusan, et al.
The Lancet. Haematology|December 22, 2015
(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation studyPatrice Chevallier, Thomas Eugene, Nelly Robillard, et al.
The New England Journal of Medicine|March 2, 2017
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic LeukemiaHagop Kantarjian, Anthony Stein, Nicola Gökbuget, et al.
Leukemia Research|February 8, 2017
TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AMLAminetou Mint Mohamed, Marie Balsat, Catherine Koering, et al.
Blood|June 17, 2022
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trialStéphane de Botton, Pau Montesinos, Andre C Schuh, et al.
Blood Advances|June 5, 2023
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized studyPierre Fenaux, Marco Gobbi, Patricia L Kropf, et al.
Blood Advances|October 25, 2024
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OSThomas Cluzeau, Fabio Guolo, Edmond Chiche, et al.
Blood|April 20, 2022
Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO studyNicolas Duployez, Laëtitia Largeaud, Matthieu Duchmann, et al.
American Journal of Hematology|April 2, 2020
Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III studyFrédéric Baron, Fabio Efficace, Laura Cannella, et al.
Pageof 27